Loading...
Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma
Danilov, A. V. Kambhampati Thiruvengadam, S. Linton, K. Cumings, K. Chirikov, V. Mutebi, A. Bains Chawla, S. Chhibber, A. Rivas Navarro, F. Marques Gonçalves, F.
Danilov, A. V.
Kambhampati Thiruvengadam, S.
Linton, K.
Cumings, K.
Chirikov, V.
Mutebi, A.
Bains Chawla, S.
Chhibber, A.
Rivas Navarro, F.
Marques Gonçalves, F.
Abstract
This matching-adjusted indirect comparison evaluated the efficacy of epcoritamab vs standard of care (SOC), mosunetuzumab, or odronextamab, and assessed safety vs mosunetuzumab and odronextamab. Individual patient-level data from the EPCORE NHL-1 follicular lymphoma (FL) cohort for epcoritamab were used with pooled data from SCHOLAR-5 for SOC (mostly chemoimmunotherapy [CIT]), and aggregate data from GO29781 for mosunetuzumab and ELM-2 for odronextamab. Trial populations were match-adjusted using propensity score weights for key baseline characteristics. Compared with SOC/CIT, epcoritamab provided significantly higher response rates (overall response rate [ORR], 90.9% vs 56.8%; P < .001; complete response [CR] rate, 73.7% vs 32.0%; P < .001). Epcoritamab showed numerically higher ORR (90.9% vs 80.0%; P = .067) and CR rate (72.8% vs 60.0%; P = .159) vs mosunetuzumab. Epcoritamab provided significantly higher ORR (91.5% vs 80.5%; P = .026) and numerically lower CR rate (67.5% vs 73.4%; P = .428) vs odronextamab. Epcoritamab did not have any grade ≥3 cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS; any grade) events compared with CRS (grade ≥3) in 2.2% and 3.9% and ICANS in 4.4% and 0.8% of patients treated with mosunetuzumab and odronextamab, respectively (P < .001). In addition to being a convenient subcutaneous option, epcoritamab showed significantly superior response rates and survival outcomes vs SOC/CIT among patients with relapsed or refractory FL after ≥2 systemic therapies. Epcoritamab also exhibited clinically relevant, numerically higher ORRs and demonstrated improved safety for CRS (grade ≥3) and ICANS vs mosunetuzumab or odronextamab. These trials were registered at www.ClinicalTrials.gov as #NCT03625037, #NCT02500407, and #NCT03888105.
Description
Date
2025
Publisher
Collections
Files
Loading...
Found in Unpaywall
Adobe PDF, 787.62 KB
Keywords
Type
Article
Citation
Danilov AV, Kambhampati Thiruvengadam S, Linton K, Cumings K, Chirikov V, Mutebi A, et al. Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma. Blood advances. 2025 Aug 12;9(15):3754-65.